Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) does about 2.02M shares in volume on a normal day but saw 3495014 shares change hands in Monday trading. The company now has a market cap of 15.67M USD. Its current market price is $0.19, marking an increase of 6.98% compared to the previous close of $0.17. The 52 week high reached by this stock is $3.75 whilst the lowest price level in 52 weeks is $0.17.
Tonix Pharmaceuticals Holding Corp (TNXP) has a 20-day trading average at $0.2854 and the current price is -95.05% off the 52-week high compared with 11.08% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.3242 and its 200-day simple moving average is $0.6804. If we look at the stock’s price movements over the week, volatility stands at 8.42%, which increases to 13.81% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 27.30 to suggest the stock is oversold.
The consensus objective for the share price is $3.75, suggesting that the stock has a potential upside of 94.93% over the period.
ROTH Capital upgraded the stock to “Buy” from Neutral on April 18, 2019 at a price target of $4. ROTH Capital upgraded its price target at $6.
Tonix Pharmaceuticals Holding Corp (TNXP) stock is down -2.32% over the week and -50.29% over the past month. Its price is -53.97% year-to-date and -94.95% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2023, with the company’s earnings per share (EPS) of -$0.86 above consensus estimates by $0.78. TNXP’s earnings per share are forecast to grow by 54.20% this year and 61.50% over next year. Expected sales for next quarter are $7.9 million, which analysts say will come at $16.77 million for the current fiscal year and next year at $24.5 million. In addition, estimates put the company’s current quarterly revenue at an average of $7.5 million.
To reach the target analysts have set, the stock logically needs to grow 94.93 percent from here.
Outstanding shares total 84.49M with insiders holding 0.01% of the shares and institutional holders owning 28.61% of the company’s common stock. The company has a return on investment of -103.50% and return on equity of -74.61%. The beta has a value of 2.22. Price to book ratio is 0.10 and price to sales ratio is 2.02.
